Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes

Melanie C. Dispenza, Bruce S. Bochner*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Purpose of Review: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. Recent Findings: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole and anti-Siglec-8 antibody show promise, but need to be confirmed in randomized trials. Summary: Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalCurrent Hematologic Malignancy Reports
Issue number3
StatePublished - Jun 1 2018


  • Biologic
  • Dexpramipexole
  • Hypereosinophilic syndrome
  • IL-5
  • Siglec-8
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes'. Together they form a unique fingerprint.

Cite this